Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Enteric coated gelatin hollow capsules BP EP USP pharma grade offer a targeted delivery system meant for medication that must reach the intestines before dissolving. In my years working with pharmaceutical formulations, the challenge with many active ingredients comes down to protecting them from degradation in the stomach’s harsh acidic environment. These capsules address that issue by adding a stable gelatin shell finished with an enteric polymer coat, creating a shell that resists dissolution below pH 5.5, but starts to break down once it comes into contact with intestinal fluids. The design reflects a focus on combining the time-tested safety and biocompatibility of pharmaceutical-grade gelatin—sourced from bovine or porcine collagen—with today’s more advanced gastrointestinal targeting needs.
Each capsule holds a lightweight, rigid shell, shaped in cylindrical form and colorless or tinted, depending on the specific application. They appear as solid, dry capsules with a smooth, sleek surface designed to minimize static friction and maintain tight manufacturing tolerances. Sizes run from the smallest 5 through the large 000, aligning with BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) standards. Specific density for these gelatin shells generally falls between 1.26–1.35 g/cm³, with moisture content maintained below 14% to hold consistency and avoid brittleness. My experience tells me improper moisture control can lead to shells cracking during filling or sticking on machinery—manufacturers run regular in-process moisture and density checks, using calibrated meters to ensure shells stay robust and functional through packaging and transport. The uniform molecular structure keeps them light enough for easy filling but tough enough to survive automated handling and encapsulation lines without breaking.
Gelatin, the main raw material, is a protein derived from the partial hydrolysis of collagen, holding the empirical formula C102H151O39N31 for pure gelatin chains but always featuring some level of variability. For the enteric coat, common polymers include phthalate- or acrylate-based compounds—like hydroxypropyl methylcellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), or methacrylic acid copolymers. Enteric polymers trigger shell integrity by employing molecular crosslinks that remain inert in acid but ionize and dissolve in basic pH, allowing precisely controlled release. Each component used meets pharma raw material regulations—free from harmful heavy metals, dioxin, or other hazardous contaminants—screened under pharmacopoeial monographs and subject to regular lot traceability. Suppliers must certify source traceability for gelatin, particularly after high-profile safety incidents decades ago, and both gelatin and enteric polymers come with full documentation for microbial, viral, and prion safety.
For global trading, enteric coated gelatin hollow capsules classify under Harmonized System Code 96020000—surgical, medical, and sanitary articles. Customs clearance officers often look for precise documentation matching this code, ensuring the goods pass smoothly through international borders. As a pharma-grade excipient, these capsules face regulatory reviews set by health authorities like FDA, EMA, and CFDA. BP, EP, and USP standards dictate every lot’s microbial limits, dissolution, residual moisture, and mechanical resilience. I have seen multiple batches detained at customs when technical documentation fell short, so companies holding certificates of analysis and clear HS coding minimize supply chain interruptions and regulatory backlogs.
These capsules arrive as solid, rigid cylindrical tubes. They aren't available as flakes, powder, pearls, or liquid—instead, they rely on finished, ready-to-fill shells. Crystal form appears smooth and glassy due to the gelatin’s protein chains aligning during drying. Density remains strictly controlled for accurate shell volume and robust packaging, while the solid nature ensures each unit delivers a consistent dose and resists crushing or moisture uptake during storage. Liquid solutions come into play earlier in the manufacturing process when gelatin and enteric coatings get mixed and pumped into capsule molds or dipping tanks. For suppliers and pharmacists, physical form signals quality—any irregularity in shell translucence, color distribution, or mechanical toughness can flag a faulty batch, which must be quarantined to avoid costly recalls or consumer risks.
Gelatin capsules themselves show a well-cataloged safety profile. Administered orally and digested enzymatically, pharmaceutical gelatin does not bioaccumulate or present toxicity in therapeutic doses. Regulatory bodies, including the WHO and national food safety agencies, establish limits on residual solvents and banned processing agents. For the enteric polymer, compliance with USP, BP, and EP monographs provides assurance against hazardous leachables or extractables—these coatings break down safely inside the body. The real hazard emerges when substandard raw materials or unregulated production slip through—past material scandals involving industrial-grade gelatin or mixed animal sources show the harm from poor oversight. Factories run on-site tests for endotoxins, microbial load, BSE/TSE risk, and prohibited preservatives, discarding tanks that test positive above thresholds. For workers, dust from gelatin powder can cause mild irritation, but robust ventilation and PPE keeps risks low. Finished capsules ship sealed in tamper-evident blister packs for extra protection.
Sourcing raw gelatin raises animal welfare and sustainability issues as it stems from livestock by-products. With consumer demand shifting, some manufacturers move toward plant-based or synthetic alternatives, but standard pharma-grade gelatin capsules still dominate due to reliability and cost. In my view, full transparency over the animal origins and ethical supply chains helps maintain public trust. Farms used for raw materials undergo audits to validate humane treatment and traceability, addressing growing scrutiny from regulators and advocacy groups. Newer projects push for closed-loop manufacturing with recycled wash water and minimized chemical waste, reducing the environmental impact compared to older open-system facilities. Past mishaps involving industrial waste from poorly managed manufacturing underscore industry responsibility for community health and ecological safety. While the bulk of capsules make their way harmlessly through healthcare channels, vigilance in waste collection and safe disposal at the pharmacy or hospital level helps avoid microplastic pollution and cross-contamination with household trash.
Improvement means technology paired with accountability—using spectroscopic testing for rapid screening of incoming gelatin and polymer lots, verifying not just purity but correct origin. Full digitization of supply chain records cuts down on paperwork mistakes and supports real-time batch tracking if issues arise. Alternative materials like Pullulan and HPMC provide viable plant-based options for niche markets, but advances in coating polymers may soon create hybrid capsule shells that keep the acid resistance of current enteric brands but draw from renewable feedstock. For widespread adoption, regulatory harmonization matters. The same standards from USP, BP, and EP need matching with China’s ChP and Japan’s JP, avoiding needless duplication and simplifying global manufacturing. All progress comes back to basics: safe raw material sourcing, verified clean production, and reliable delivery performance. Transparency, responsible sourcing, and constant quality monitoring lay the groundwork for trusted, effective medicines—whether carried inside traditional gelatin shells or emerging bio-polymer alternatives.
Chengguan District, Lanzhou, Gansu, China
